- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 17,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- High Risk Acute Myeloid Leukemia
- Interventions
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 31 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- Cyclophosphamide, Fludarabine, Anti-thymocyte globulin, Myeloablative Busulfan, Mesenchymal stem cell transplantation, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation
- Drug · Procedure · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- AGS15E
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Detroit, Michigan + 5 more
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
- Interventions
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
- Conditions
- Bulimia
- Interventions
- GSKI181771X (CCK-1R agonist), Instructions to binge eat, Instructions to eat normally, Placebo
- Drug · Behavioral
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- OSI-906, Everolimus
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Nashville, Tennessee
- Conditions
- Healthy Volunteers
- Interventions
- Caplacizumab Dose 1 iv (single-dose), Caplacizumab Dose 2 iv (single-dose), Caplacizumab Dose 2 sc (single-dose), Caplacizumab Dose 2 sc (multiple-dose), Placebo iv (single-dose), Placebo sc (single-dose), Placebo sc (multiple-dose)
- Biological · Other
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Diabetes Mellitus
- Interventions
- JTT-252 or Placebo, JTT-252
- Drug
- Lead sponsor
- Shionogi Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Austin, Texas
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Interventions
- Alpelisib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Days to 100 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more
- Conditions
- Renal Failure
- Interventions
- Everolimus, Sirolimus
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pre-diabetes, Obesity
- Interventions
- Chronic salsalate, Acute Salsalate
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hypertension, Pulmonary
- Interventions
- Tadalafil, Placebo, ERA as specific PAH treatment
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
- Conditions
- Advanced Solid Tumor
- Interventions
- vilastobart (XTX101), Atezolizumab
- Drug
- Lead sponsor
- Xilio Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Duarte, California • Encinitas, California + 16 more
- Conditions
- Renal Impairment, Healthy
- Interventions
- PF-07328948
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more
- Conditions
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Nipocalimab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 16
- States / cities
- Centennial, Colorado • Coral Springs, Florida • Maitland, Florida + 13 more
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
- Interventions
- GPC2 CAR T cells
- Biological
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- DIRA
- Interventions
- Rilonacept
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 3 Months and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation, WHO Grade 3 Glioma With 1p/19q Codeletion
- Interventions
- Proton radiation
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Influenza
- Interventions
- Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose, Fluzone®; Influenza Virus Vaccine, No Preservative
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 8 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Bardstown, Kentucky • Salt Lake City, Utah
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Clofarabine
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Thromboembolism
- Interventions
- Coumadin
- Drug
- Lead sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Melanoma
- Interventions
- Epacadostat, ipilimumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
- Interventions
- Ibuprofen and acetaminophen, Ibuprofen and placebo
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 5 Days to 21 Days
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Mobile, Alabama